OR WAIT null SECS
June 23, 2025
Podcast
Discover how the CATALYST trial reveals mifepristone's potential to enhance glycemic control and weight loss in challenging type 2 diabetes cases.
Article
Mifepristone shows promise in improving glycemic control and reducing weight in patients with hypercortisolism and type 2 diabetes.
Maridebart cafraglutide shows potential as a monthly treatment for obesity and type 2 diabetes, demonstrating significant weight loss and glycemic improvements.
Video
Sandforth emphasized the important of achieving prediabetes remission for preventing T2D as seen in his new research.
Explore groundbreaking findings from the REDEFINE trials on CagriSema's impact on weight loss and diabetes management at ADA 2025.
June 22, 2025
Philis-Tsimikas shared the latest findings demonstrating inferiority after switching from daily basal insulin to weekly insulin efsitora.
Kevin Sayer joins the program to discuss the latest from Dexcom and preview where the business is headed in an evolving diabetes landscape.
A new study reveals once-weekly efsitora alfa effectively lowers blood glucose in type 2 diabetes.
Steger discussed findings from a 6-month lifestyle investigating TRE+ER and IER.
A global study reveals that universal access to semaglutide could save 28 million lives and significantly reduce obesity and diabetes worldwide.
